Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 124Myelodysplastic Syndromes 119Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 85Hodgkin Disease 80Leukemia, Lymphocytic, Chronic, B-Cell 77Lymphoma 75Multiple Myeloma 74Lymphoma, Non-Hodgkin 74Myeloproliferative Disorders 57Graft vs Host Disease 55Lymphoma, Follicular 53Lymphoma, Mantle-Cell 49Lymphoma, Large B-Cell, Diffuse 49Leukemia, Myeloid, Accelerated Phase 49Leukemia, Myelomonocytic, Chronic 48Leukemia, Myelogenous, Chronic, BCR-ABL Positive 47Congenital Abnormalities 47Hematologic Neoplasms 45Leukemia, Myeloid, Chronic-Phase 44Lymphoma, B-Cell, Marginal Zone 43Primary Myelofibrosis 41Burkitt Lymphoma 41Blast Crisis 38Neoplasms, Plasma Cell 37Lymphoma, Large-Cell, Immunoblastic 33Waldenstrom Macroglobulinemia 25Myelodysplastic-Myeloproliferative Diseases 25Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25Anemia, Refractory, with Excess of Blasts 24

Interventions

Cytarabine 7Mitoxantrone 3Cyclophosphamide 3venetoclax 2thymoglobulin 2fludarabine phosphate 2fludarabine 2devimistat 2Thiotepa 2Tacrolimus 2Rituximab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Daunorubicin 2Cladribine 2vosaroxin 1quizartinib 1plerixafor 1pegylated granulocyte colony-stimulating factor 1blinatumomab 1aldesleukin 1Transplantation 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Razoxane 1Mycophenolic Acid 1Metformin 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Myeloid × Tacrolimus × Clear all
NCT02790515 2025-08-12

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
170 enrolled
LymphoidMyeloidOther hematologic neoplasmSarcoma

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Sarcoma, Myeloid, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT01621477 2017-02-20

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

St. Jude Children's Research Hospital

Phase 2 Terminated
34 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasmSarcoma

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡